164 related articles for article (PubMed ID: 38687039)
1. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S
Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
[TBL] [Abstract][Full Text] [Related]
2. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ; Hønge BL; Wejse CM
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
[TBL] [Abstract][Full Text] [Related]
4. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
Paneerselvam N; Khan A; Lawson BR
Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
7. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.
Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P
J Virol; 2021 May; 95(12):. PubMed ID: 33827946
[TBL] [Abstract][Full Text] [Related]
8. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
Front Immunol; 2021; 12():697683. PubMed ID: 34354709
[TBL] [Abstract][Full Text] [Related]
9. Broadly Neutralizing Antibodies for HIV Prevention.
Karuna ST; Corey L
Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A; Balazs AB
Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
[TBL] [Abstract][Full Text] [Related]
11. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
15. Broadly neutralizing antibodies for HIV-1 prevention and therapy.
Julg B; Barouch D
Semin Immunol; 2021 Jan; 51():101475. PubMed ID: 33858765
[TBL] [Abstract][Full Text] [Related]
16. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
18. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
[TBL] [Abstract][Full Text] [Related]
19. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.
Spencer DA; Shapiro MB; Haigwood NL; Hessell AJ
Front Public Health; 2021; 9():690017. PubMed ID: 34123998
[TBL] [Abstract][Full Text] [Related]
20. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
